"CAP" Fetge Gras. Lifestyle Modification Program in Catalonia.

  • days left to enroll
  • participants needed
  • sponsor
    Hospital Clinic of Barcelona
Updated on 14 August 2021


The main purpose of this study is to investigate whether an online lifestyle modification program for people with Metabolic Associated Fatty Liver Disease (MAFLD) through a mobile application produces a significant reduction in liver steatosis and is associated with a higher rate of weight loss compared to standard recommendations currently indicated in Primary Care.


Chronic liver disease are very common and potentially severe. For the most part, they are diagnosed in an advanced stage, which prevents the introduction of curative treatments.

MAFLD is currently the most common cause of chronic liver disease affecting approximately 25% of the world's population. MAFLD is characterized by an excessive accumulation of liver fat associated with insulin resistance (IR) which is defined by the presence of steatosis in> 5% of hepatocytes according to histological analysis.

Currently, the only effective strategy for treating MAFLD is weight loss. Several studies show that a 3-5% weight loss manages to reduce hepatic steatosis and associated metabolic parameters. Despite this, a reduction of at least 7-10% is required to improve fibrosis. Guidelines from the European Association for the Study of Liver Diseases (EASL) and the American Association for the Study of Liver Diseases (AASLD) recommend following an energy-restricted diet adjusted to the Mediterranean diet, excluding MAFLD-promoting components (processed products and high in added fructose), and perform physical activity in order to achieve this goal. However, it is a difficult goal to achieve and maintain over time. Epidemiological evidence recommends implementing structured lifestyle modification programs with the goal of losing weight.

In people with MFGNA, participation in structured lifestyle programs may be compromised by work and time constraints. An application-based online intervention may be more appropriate for young people, people of working age, and those living far from primary care. EHealth technology is a possible resource for promoting behavior change but is a little-studied field in lifestyles modification of people with MAFLD. Given the lack of information regarding lifestyle modification programs in people with MAFLD as the main therapeutic intervention in Primary Care (PC), we consider to analyze the effectiveness of an online program based on the Mediterranean diet with calorie restriction, associated with specific goals of weight loss and physical activity, which allows to reduce hepatic steatosis of individuals with MAFLD.

This study, along with studies of early detection of chronic liver disease through liver elastography "LiverScreen", aims to be the beginning of the approach to chronic liver disease in Primary Care. The aim of this study is to evaluate a strategy for treating MAFLD.

Condition Liver Disease, liver diseases, hepatic pathology, LIVER DISEASE, Lifestyle, Healthy, hepatopathy, hepatic disease, NAFLD, Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver Disease, hepatic diseases, non-alcoholic fatty liver, Liver Disorders, Nonalcoholic Steatohepatitis (NASH)
Treatment Control group, Intervention CFG App
Clinical Study IdentifierNCT04988633
SponsorHospital Clinic of Barcelona
Last Modified on14 August 2021


Yes No Not Sure

Inclusion Criteria

Age 18 years old
Fibroscan with a CAP 300 dB/m and liver stiffness <8 Kpa

Exclusion Criteria

Serious chronic disease (heart, respiratory, cancer, etc.)
Chronic liver disease
Chronic kidney disease (FGR <60ml/min)
Weight loss> 5% during the last three months
Impossibility to follow the recommended diet (for religious reasons, swallowing problems, etc.) or inability to perform physical activity
Inability to follow the scheduled visits to the intervention (institutionalized individuals, lack of autonomy, inability to walk, lack of a stable home, travel plans, etc.)
Have been included in another weight loss advice program (>5 kg) during the 6 months prior to the selection visit (basal visit)
History of having followed a low calorie diet (<900Kcal/day) for the last 6 months
History of surgical procedures to lose weight or intend to undergo bariatric surgery in the next 12 months
Hemoglobin A1c 9%
History of resection of the small or large intestine
History of inflammatory bowel disease
BMI> 40 or obesity of known endocrine origin (with the exception of treated hypothyroidism)
Current treatment with systemic corticosteroids
Current use of medication for weight loss
Current treatment with steatogenic drugs
People participating in a clinical trial with drugs
Patients with mental incapacity, language barrier, bad social support or any other reason considered by the investigator precluding adequate understanding, cooperation or compliance in the study
Refusal to give informed consent
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note